IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of comprehensive income for the year ended December 31

in CHF 1 000

 

Notes

 

2021

 

2020

Operating income

 

 

 

 

 

 

Net gains from securities

 

4

 

 

741 511

Interest income

 

 

 

 

7

Dividend income

 

 

 

 

243

Other income

 

 

 

4

 

23

 

 

 

 

4

 

741 784

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

Net losses from securities

 

4

 

(343 595)

 

Finance expenses

 

 

 

(986)

 

(883)

Foreign exchange losses

 

 

 

(962)

 

(1 857)

Administrative expenses

 

8

 

(52 595)

 

(41 755)

Other expenses

 

9

 

(6 607)

 

(6 040)

 

 

 

 

(404 745)

 

(50 535)

Profit/(loss) before tax

 

12

 

(404 741)

 

691 249

 

 

 

 

 

 

 

Income taxes

 

10

 

(67)

 

(75)

Profit/(loss) for the period

 

 

 

(404 808)

 

691 174

 

 

 

 

 

 

 

Total comprehensive profit/(loss) for the period

 

 

 

(404 808)

 

691 174

 

 

 

 

 

 

 

Earnings/(loss) per share in CHF

 

11

 

(7.31)

 

12.48

Diluted earnings/(loss) per share in CHF

 

11

 

(7.31)

 

12.48

The notes are an integral part of the consolidated financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer